Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. El Hasnaoui is active.

Publication


Featured researches published by A. El Hasnaoui.


Environmental Research | 2003

Indoor aldehydes: measurement of contamination levels and identification of their determinants in Paris dwellings.

B. Clarisse; Anne-Marie Laurent; N. Seta; Y. Le Moullec; A. El Hasnaoui; I Momas

The recent increased prevalence of childhood asthma and atopy has brought into question the impact of outdoor pollutants and indoor air quality. The contributory role of aldehydes to this problem and the fact that they are mainly derived from the domestic environment make them of particular interest. This study therefore measures six different aldehyde levels in Paris dwellings from potentially different sources and identifies their indoor determinants. The study was carried out in the three principal rooms of 61 flats with no previous history of complaint for olfactory nuisance or specific symptoms, two-thirds of the flats having been recently refurbished. Aldehydes were sampled in these rooms using passive samplers, and a questionnaire on potential aldehyde sources was filled out at the same time. A multiple linear regression model was used to investigate indoor aldehyde determinants. Our study revealed that propionaldehyde and benzaldehyde were of minor importance compared to formaldehyde, acetaldehyde, pentanal, and hexanal. We found that levels of these last four compounds depended on the age of wall or floor coverings (renovations less than 1 year old), smoking, and ambient parameters (carbon dioxide levels, temperature). These results could help in the assessment of indoor aldehyde emissions.


Allergy | 2005

Prevalence of nasal polyposis in France: a cross-sectional, case-control study

Jean-Michel Klossek; Françoise Neukirch; C. Pribil; R. Jankowski; E. Serrano; I. Chanal; A. El Hasnaoui

Background:  The prevalence of nasal polyposis (NP) has never been established in France due to the lack of diagnostic tools for population‐based studies.


Sexually Transmitted Infections | 2002

Seroprevalence of HSV-1 and HSV-2 infection in the general French population.

J-E Malkin; P. Morand; D. Malvy; T D Ly; Bruno Chanzy; C. De Labareyre; A. El Hasnaoui; Serge Hercberg

Background: In spite of the large prevalence and growing incidence of herpes simplex infection (HSV-1 and HSV-2), relatively few large serological surveys are available worldwide and it is still difficult compare frequencies of HSV contaminations in various countries. We present the results of HERPIMAX, the first epidemiological inquiry on HSV prevalence in the general French population. Methods: Of a cohort of 12 735 presumed healthy adult volunteers included in the prospective study SU.VI.MAX, designed to assess the relation between nutritional supplementations and degenerative diseases, HERPIMAX randomly selected 4412 subjects (females 66.5%, males 33.5%). All serum samples were assessed for HSV-1 and HSV-2 IgG antibodies with a HSV type specific, enzyme immunosorbent assay (EIA). Equivocal result were retested with another HSV type specific immunoblot assay combined with a type common HSV IgG EIA in order to give a definitive interpretation. Results: The mean seroprevalence was 67% for HSV-1 and 17.2% for HSV-2. For HSV-2 the seroprevalence was higher in females (17.9%) compared with males (13.7%) (p <0.001). For both HSV types, there was no significant difference in prevalence as regards age distribution in males and females, whereas prevalence increased significantly with age in females for HSV-1. Univariate analysis showed a significant association between HSV-1 prevalence and education level in males and females (p <0.001) and between HSV-2 prevalence and marital status in both sexes (p <0.001). There were geographical disparities, with a higher HSV-2 prevalence in the south of France as well as in Paris. Conclusion: These results confirm a high prevalence of HSV infection in France. They are also in agreement with previous results of other survey carried out in other developed countries as regards higher prevalence of HSV-2 infection in women, the stability of seroprevalence for both HSV types after 35 years of age in females and 45 years of age in males.


European Journal of Neurology | 2005

Use of the headache impact test (HIT-6) in general practice: relationship with quality of life and severity

F. Nachit-Ouinekh; Jean-François Dartigues; Patrick Henry; J.-P. Becg; G. Chastan; N. Lemaire; A. El Hasnaoui

To assess the global impact of episodic headaches in patients consulting general practitioners (GPs) using the Headache Impact Test (HIT‐6) questionnaire, and to compare this with measures of headache severity and quality of life. A total of 2802 patients consulting 349 GPs participated to this cross‐sectional study. Data were collected on headache severity using the Migraine Severity (MIGSEV) scale, headache impact with the HIT‐6 and quality of life with the Qualité de Vie et Migraine (QVM) questionnaire. Diagnosis was assigned retrospectively according to the International Headache Society criteria. The association between the HIT‐6 scale and the other scales was determined from a Pearsons chi‐square test, an analysis of variance and Spearman correlation coefficients. Patients (2537) provided exploitable data. Six percent of the sample had little impact, 14% moderate, 14% substantial and 66% severe impact. The HIT‐6 scores were significantly different between diagnostic groups, being highest in the migraine group. The HIT‐6 score were well correlated with headache severity and QVM score. The HIT‐6 scale correlates, across different diagnostic groups of headache, with both headache severity and with quality of life.


Cephalalgia | 2009

The GRIM2005 Study of Migraine Consultation in France. III: Psychological Features of Subjects With Migraine

Françoise Radat; Michel Lanteri-Minet; F. Nachit-Ouinekh; Hélène Massiou; Christian Lucas; André Pradalier; F Mercier; A. El Hasnaoui

The objective of this analysis was to describe psychological and cognitive variables in subjects with migraine and to identify those associated with chronicity. Data were collected from 10 000 subjects during face-to-face interview. Subjects with episodic migraine (n = 1127) or chronic daily headache (n = 407) with migrainous features were identified using an algorithm based on the International Classification of Headache Disorders, 2nd edn classification. Data on headache impact was obtained with the Headache Impact Test-6, on psychological distress with the Hospital Anxiety and Depression Scale, on coping with the Coping Strategy Questionnaire catastrophizing score and the Brief COPE inventory, on illness perception with the Brief Illness Perception Questionnaire and on locus of control. Psychological variables associated with chronicity include perceived headache impact, psychological distress, the use of catastrophizing and avoidance coping strategies and an externalized locus of control. In conclusion, maladaptive coping strategies should be taken into account in the management of patients with migraine. Longitudinal studies will be necessary to address the causality of the relationship observed.


Cephalalgia | 2004

Use and Misuse of Triptans in France: Data from the Grim2000 Population Survey

Christian Lucas; Anne-Françoise Gaudin; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lanteri-Minet; André Pradalier; Guy Chazot; A. El Hasnaoui

The extent and nature of triptan use for headache relief has been evaluated in a large epidemiological survey in the French general population. Over 25 000 individuals were screened for headache and for triptan use. Of this sample, 290 triptan users were identified from whom extensive data on headache characteristics and healthcare resource consumption were obtained. The use of triptans is relatively infrequent, 0.2% in the general population, with only 7.5% of migraine sufferers using these drugs. The majority of triptan users were female (80%) and presented headache characteristics typical of migraine (80%). The remaining 20% of subjects were thus using triptans for headache types in which the utility of these drugs has not been demonstrated. Among migraineurs, triptan consumers reported more frequent and severe headaches than non-consumers, and reported a higher incidence of nausea and vomiting. The principal determinant of triptan prescription was consultation with a general practitioner (GP), which may itself have been triggered by the severity of the headaches. GPs, rather than specialists, are the primary prescribers of triptans in France.


Cephalalgia | 2005

Variability of reported headache symptoms and diagnosis of migraine at 12 months

F. Nachit-Ouinekh; Virginie Chrysostome; Patrick Henry; Christophe Sourgen; Jean-François Dartigues; A. El Hasnaoui

Assignment of a diagnosis of migraine has been formalized in diagnostic criteria proposed by the International Headache Society. The objective of the present study is to determine the reproductibility of the formal diagnosis of migraine in a cohort of headache sufferers over a one-year period. The study was performed in a community cohort taking part in a long-term prospective health survey, the GAZEL study. Two thousand five hundred individuals reporting headache in the GAZEL cohort were sent two postal questionnaires concerning headache symptoms and features at 12-monthly intervals. Replies to the questions allowed a migraine diagnosis to be attributed retrospectively using an algorithm based on the IHS classification scheme. The response rate was 82% for the first questionnaire and 69% for both questionnaires. Of the 1733 subjects providing information at both time-points, the agreement rate for the diagnosis of strict migraine (IHS categories 1.1 or 1.2) was 77.7% (kappa = 0.48), with 62.2% of the patients with this diagnosis (IHS categories 1.1 or 1.2) at Month 0 retaining the same diagnosis at Month 12. When diagnostic criteria were widened to include IHS category 1.7 (migrainous disorder), the agreement rate of the diagnosis was similar at 77.6% (kappa = 0.52), but 82% of the patients with this diagnosis (IHS categories 1.1 or 1.2 or 1.7) at Month 0 now retained the same diagnosis at Month 12. In conclusion, the one-year reproducibility of reporting of migraine headache symptoms is only moderate, varies between symptoms, and leads to instability in the formal assignment of a migraine headache diagnosis and to diagnostic drift between headache types. This finding is compatible with the continuum model of headache, where headache attacks can vary along a severity continuum from episodic tension-type headaches to full-blown migraine attacks.


Cephalalgia | 2004

Assessment of Migraine Severity Using the Migsev Scale: Relationship to Migraine Features and Quality of Life

A. El Hasnaoui; Muriel Vray; P. Blin; F. Nachit-Ouinekh; F Boureau

We have recently developed an instrument to describe and categorize severity of migraine attacks from patient self-report, the MIGSEV questionnaire. We have now performed a large prospective survey using this tool to evaluate migraine severity in 2979 patients consulting for headache in France, included by 1164 general practitioners, 174 neurologists and 82 gynaecologists. The objective of the study was to determine the prevalence of severity grades in a large population who consults for migraine, to test the concordance between severity calculated from physician-derived and patient-derived data, and to test the relevance of the concept of severity as applied to diagnosis, other measures of the burden of migraine, and to health-related quality of life. Severe attacks were reported in around one-fifth of the sample. Physician- and patient-derived data provided concordant estimates of severity in 71% of cases, the discordant cases representing principally an underestimate by the physician of headache severity. Migraine severity was associated with frequent, long-lasting and treatment-resistant attacks, and with poor quality of life. The MIGSEV questionnaire is proposed as a simple measure of severity for the diagnosis and management of migraineurs, suitable for use both by physicians and patients.


Journal of The European Academy of Dermatology and Venereology | 2007

Epidemiology of orofacial herpes simplex virus infections in the general population in France: results of the HERPIMAX study

D. Malvy; Khaled Ezzedine; Florian Lançon; B. Halioua; A. Rezvani; Sandrine Bertrais; Bruno Chanzy; J.-E. Malkin; P. Morand; C. De Labareyre; Serge Hercberg; A. El Hasnaoui

Background  Prevalence of clinically manifest orofacial herpes in the general population is poorly characterized.


Cephalalgia | 2007

The GRIM2005 study of migraine consultation in France II. Psychological factors associated with treatment response to acute headache therapy and satisfaction in migraine.

Christian Lucas; Michel Lanteri-Minet; Hélène Massiou; F. Nachit-Ouinekh; André Pradalier; F Mercier; A. El Hasnaoui; Françoise Radat

The objective of this analysis was to identify variables associated with treatment response in subjects with migraine. Data were collected from a sample of 10 000 subjects. A battery of questionnaires assessing clinical and psychological variables was completed. Migraine diagnosis was attributed using an algorithm based on the IHS criteria and treatment response using the ANAES criteria. We identified 1534 subjects, of whom 1443 were treated. For 54.2%, at least one ANAES criterion for treatment response was unfulfilled. Non-response was associated with female gender, high HIT-6 impact scores and high HAD psychological distress scores. The strongest associations with non-response were identified for four psychological variables: elevated scores on the CSQ catastrophization subscale and the ‘Consequences’ and ‘Acceptance’ dimensions of the Brief COPE, and low scores on the ‘Positive Reinterpretation’ Brief COPE dimension. In conclusion, many individuals with migraine respond inadequately to treatment. Behavioural interventions aimed at modifying coping strategies may improve outcome.

Collaboration


Dive into the A. El Hasnaoui's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

P. Morand

Centre Hospitalier Universitaire de Grenoble

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. Malvy

French Institute of Health and Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

E. Serrano

University of Toulouse

View shared research outputs
Researchain Logo
Decentralizing Knowledge